Creating advanced CAR T cells to better target cancer cells
Developing novel CAR T cell designs using combinatorial antigen detection
['FUNDING_CAREER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11055372
This study is working on a new type of CAR T cell therapy that helps your immune system better find and fight cancer cells, especially in blood cancers, by teaching the T cells to recognize several markers on the cancer at once, and it aims to bring these promising treatments to early clinical trials soon.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11055372 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative CAR T cell therapies that can more effectively target and eliminate cancer cells, particularly in B cell malignancies. The approach involves using combinatorial antigen detection, which allows the engineered T cells to recognize multiple tumor markers simultaneously, enhancing their ability to identify and destroy cancer cells. The project includes extensive training for the lead investigator in clinical trial design and tumor immunology, aiming to translate these new therapies into early-phase clinical trials. By improving the precision of CAR T cell therapies, this research seeks to address the limitations of current treatments for solid tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with B cell malignancies, such as B lymphoma, who have not responded to existing therapies.
Not a fit: Patients with non-B cell malignancies or those who have already responded well to current CAR T cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve survival rates and quality of life for patients with B cell malignancies.
How similar studies have performed: Other research has shown promise in using combinatorial antigen detection for improving cancer therapies, indicating that this approach could lead to significant advancements.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALLEN, GREG MANESS — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: ALLEN, GREG MANESS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy